{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-002256","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2021-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.967274+00:00","generated_at":"2026-06-28T18:26:56.953224+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Clearside's XIPERE for macular edema associated with uveitis; first suprachoroidal therapy","bullets":["XIPERE (triamcinolone acetonide injectable suspension) is the first FDA-approved therapy for suprachoroidal injection.","Phase 3 PEACHTREE trial: 47% of XIPERE patients achieved ≥15-letter BCVA improvement vs 16% sham (p<0.01) at Week 24.","Bausch + Lomb markets XIPERE; expected availability Q1 2022 under Clearside's SCS Microinjector delivery system.","This is Clearside's first commercial product and the first approved treatment specifically for macular edema associated with uveitis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-002256","json":"https://secwatch.observer/filing/0000950170-21-002256.json","markdown":"https://secwatch.observer/filing/0000950170-21-002256.md","text":"https://secwatch.observer/filing/0000950170-21-002256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021002256/0000950170-21-002256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021002256/clsd-20211025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:26:56.953224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}